omniture
上海药明康德新药开发有限公司 SHANGHAI PHARMATECHS CO.LTD

Latest News

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up...

2024-03-18 20:32 1874

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval ...

2024-02-20 21:00 2696

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to...

2024-01-08 22:00 4495

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan

SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfoli...

2023-11-09 08:00 1505

WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth

* Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to overRMB10 Bil...

2023-10-30 20:01 2037

WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022

* Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Co...

2023-07-31 18:02 3706

WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022

Revenue Up 5.8% Year-Over-Year to RMB8,964 Million Net Profit Attributable to Owners of the Company ...

2023-04-24 18:03 2066

WuXi AppTec Named "Industry Mover" in S&P Global Sustainability Yearbook 2023

SHANGHAI, Feb. 15, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...

2023-02-16 08:00 1774

WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index

SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufactu...

2022-12-21 08:00 2028

WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan

SHANGHAI, Nov. 29, 2022 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...

2022-11-30 08:00 2070

WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion

Revenue Up 71.9% Year-Over-Year to RMB28,395 Million Net Profit Attributable to Owners of the Compa...

2022-10-26 19:06 3142

WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

New facility expands integrated drug product R&D and manufacturing services to global customers SH...

2022-09-26 20:00 1370

WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers

SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the ...

2022-09-09 20:00 1458

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development,...

2022-08-17 01:47 4057

WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

PHILADELPHIA, Aug. 11, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subs...

2022-08-12 09:09 1743

WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation

SINGAPORE, July 19, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufact...

2022-07-19 17:59 3801

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

Site Enhances New Modality CRDMO Platform Capacity for Customers SHANGHAI , July 6, 2022 /PRNewswir...

2022-07-07 08:00 3409

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 15, 2022 /PRNewswire/ -- WuXi Advanced Therapies...

2022-06-16 08:00 1671

WuXi AppTec Reports Record First-Quarter In 2022

Revenue Up 71.2% Year-Over-Year to RMB8,474 Million Net Profit Attributable to Owners of the Compa...

2022-04-25 17:52 2454

WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics

SHANGHAI, April 7, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufactu...

2022-04-08 08:00 1697
123